Global Commercial
Businesses

Pfizer Vaccines is uniquely positioned as a future leader in the modern vaccine era. This is true both for the development of novel vaccines to prevent infectious diseases of continuing and emerging importance, and for the development of therapeutic vaccines that provide alternative treatments to manage and control disease. Pfizer envisions a shift, with immunizations moving from a one-time intervention in infancy to a solution that fosters health and wellness through one's lifetime. We are an integrated global vaccine organization with end-to-end capabilities ranging from basic research, through process and medical development, to manufacturing and distribution. Our technological and global manufacturing capabilities are state-of-the-art, and our R&D and medical vaccine leaders are global industry innovators, all of whom have had significant vaccine experience in the industry, in academic institutions, as well as in non-governmental and governmental organizations. Collectively, the Pfizer Vaccines team has the experience and steadfast dedication to protect lives with innovative vaccines that fight serious diseases worldwide.

The goal of Pfizer Oncology is to cure or control cancer by developing breakthrough medicines that represent great value to patients, their caregivers and society. On February 3, 2015, the U.S. Food and Drug Administration (FDA) granted accelerated approval of Ibrance^® (palbociclib), in combination with letrozole, for the treatment of post-menopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease. Ibrance, an oral kinase inhibitor, was reviewed and approved under the FDA's Breakthrough Therapy designation and Priority Review programs.

In addition to the great strides that have been made over the past year making Xalkori,^® Inlyta^® and Bosulif^® available to patients around the globe, Pfizer Oncology has a promising late-stage pipeline, including investigational drugs being studied for the following indications: Ibrance (palbociclib) for both early and advanced breast cancer and additional solid tumor indications beyond breast cancer through both Pfizer-sponsored and non-sponsored (investigator-initiated) studies, inotuzumab ozogamicin for acute lymphoblastic leukemia and dacomitinib for non-small cell lung cancer. Additionally, Pfizer is working to advance the science in immuno-oncology and actively exploring a variety of novel approaches, including checkpoint modulating antibodies, CAR-T therapies, bi-functional monoclonal antibodies and vaccine-based immunotherapy regimens. Pfizer is also exploring the full potential of combining immunotherapies with its broad oncology portfolio through the company's own development efforts, as well as in collaboration with other partners, working together to improve outcomes for patients with cancer.